IL239783B - Enzyme cystathionine beta-synthase for the treatment of homo-cysteine in the devil - Google Patents
Enzyme cystathionine beta-synthase for the treatment of homo-cysteine in the devilInfo
- Publication number
- IL239783B IL239783B IL23978315A IL23978315A IL239783B IL 239783 B IL239783 B IL 239783B IL 23978315 A IL23978315 A IL 23978315A IL 23978315 A IL23978315 A IL 23978315A IL 239783 B IL239783 B IL 239783B
- Authority
- IL
- Israel
- Prior art keywords
- homocystinuria
- treatment
- synthase enzyme
- cystathionine beta
- cystathionine
- Prior art date
Links
- 108010073644 Cystathionine beta-synthase Proteins 0.000 title 1
- 206010020365 Homocystinuria Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
- C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361758138P | 2013-01-29 | 2013-01-29 | |
| US13/803,804 US9034318B2 (en) | 2011-08-30 | 2013-03-14 | Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria |
| PCT/US2014/013602 WO2014120770A1 (en) | 2013-01-29 | 2014-01-29 | Cystathionine beta-synthase enzyme for treatment of homocystinuria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL239783A0 IL239783A0 (en) | 2015-08-31 |
| IL239783B true IL239783B (en) | 2019-10-31 |
Family
ID=51223166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL23978315A IL239783B (en) | 2013-01-29 | 2015-07-05 | Enzyme cystathionine beta-synthase for the treatment of homo-cysteine in the devil |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9034318B2 (OSRAM) |
| EP (4) | EP3282013B1 (OSRAM) |
| JP (4) | JP6453243B2 (OSRAM) |
| CN (2) | CN105452457A (OSRAM) |
| AU (3) | AU2014212471B2 (OSRAM) |
| BR (1) | BR112015017775A2 (OSRAM) |
| CA (1) | CA2898772A1 (OSRAM) |
| DK (1) | DK3712264T5 (OSRAM) |
| FI (1) | FI3712264T3 (OSRAM) |
| HK (1) | HK1213291A1 (OSRAM) |
| IL (1) | IL239783B (OSRAM) |
| PT (1) | PT3712264T (OSRAM) |
| WO (1) | WO2014120770A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003251550A1 (en) | 2002-06-17 | 2003-12-31 | The Regents Of The University Of Colorado | HUMAN CYSTATHIONINE Beta-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF |
| US9034318B2 (en) * | 2011-08-30 | 2015-05-19 | The Regents Of The University Of Colorado, A Body Corporate | Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria |
| US9675678B2 (en) | 2013-01-29 | 2017-06-13 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treatment of homocystinuria |
| HUE066137T2 (hu) | 2013-10-18 | 2024-07-28 | Novartis Ag | A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére |
| HRP20220407T1 (hr) | 2015-11-09 | 2022-05-27 | The Regents Of The University Of Colorado, A Body Corporate | Pripravci i postupci za uporabu u liječenju homocistinurije |
| MX2019012347A (es) * | 2017-04-17 | 2020-01-15 | Univ Colorado Regents | Optimizacion de terapia de reemplazo enzimatico para el tratamiento de la homocistinuria. |
| US11033612B2 (en) * | 2017-05-12 | 2021-06-15 | Board Of Regents, The University Of Texas System | Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria |
| US20190309271A1 (en) | 2018-03-20 | 2019-10-10 | Rubius Therapeutics, Inc. | Therapeutic cell systems and methods for treating homocystinuria |
| CN108795913B (zh) * | 2018-05-04 | 2021-07-02 | 山西大学 | 一种植物中能催化h2s产生的酶及其应用 |
| AR116866A1 (es) | 2018-10-26 | 2021-06-23 | Univ Texas | Enzimas de degradación de cistina / cisteína de primates modificadas por ingeniería genética |
| FI3990005T3 (fi) | 2019-06-26 | 2025-11-28 | Travere Therapeutics Switzerland Gmbh | Pegyloitu kystationiini-beta-syntaasi entsyymihoitoa varten homokystinurian hoitamiseksi |
| CN114630673A (zh) * | 2019-09-03 | 2022-06-14 | 特拉维尔治疗瑞士有限公司 | 用于治疗升高的同型半胱氨酸水平的胱硫醚β-合成酶酶疗法 |
| USD1013704S1 (en) * | 2021-07-09 | 2024-02-06 | The Regents Of The University Of Colorado, A Body Corporate | Display screen or portion thereof with graphical user interface |
| USD1014518S1 (en) * | 2021-07-09 | 2024-02-13 | The Regents Of The University Of Colorado, A Body Corporate | Display screen or portion thereof with graphical user interface |
| CN115721735A (zh) * | 2022-10-13 | 2023-03-03 | 呈诺再生医学科技(北京)有限公司 | Cbs基因在制备糖尿病视网膜病变治疗药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57209206A (en) | 1981-06-08 | 1982-12-22 | Kanebo Ltd | Skin type pack agent |
| US5523225A (en) | 1993-09-13 | 1996-06-04 | Regents Of The University Of Colorado | DNA sequence encoding human cystathionine β-synthase |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5730990A (en) | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
| US5635375A (en) | 1995-01-09 | 1997-06-03 | Regents Of The University Of Colorado | Method of increasing the yield and heme saturation of cystathione β-synthase |
| US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| US6635438B2 (en) * | 1999-11-02 | 2003-10-21 | Catch, Inc. | Enzymatic cycling assays for homocysteine and cystathionine |
| AU2003251550A1 (en) * | 2002-06-17 | 2003-12-31 | The Regents Of The University Of Colorado | HUMAN CYSTATHIONINE Beta-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF |
| EP1396537A1 (en) | 2002-09-04 | 2004-03-10 | Avidis SA | Treatment of elevated plasma homocysteine |
| CN101322840A (zh) * | 2008-05-28 | 2008-12-17 | 中国人民解放军军事医学科学院卫生学环境医学研究所 | 一种人胱硫醚β-合成酶重组蛋白及应用 |
| BR112013000027A2 (pt) | 2010-07-01 | 2017-07-11 | Isis Innovation | tratamento de distúrbios cognitivos |
| US9034318B2 (en) | 2011-08-30 | 2015-05-19 | The Regents Of The University Of Colorado, A Body Corporate | Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria |
| US9243239B2 (en) | 2012-03-26 | 2016-01-26 | The Regents Of The University Of Colorado, A Body Corporate | Purification of cystathionine beta-synthase |
| US9675678B2 (en) * | 2013-01-29 | 2017-06-13 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treatment of homocystinuria |
-
2013
- 2013-03-14 US US13/803,804 patent/US9034318B2/en active Active
-
2014
- 2014-01-29 CA CA2898772A patent/CA2898772A1/en active Pending
- 2014-01-29 EP EP17172478.4A patent/EP3282013B1/en active Active
- 2014-01-29 BR BR112015017775A patent/BR112015017775A2/pt not_active Application Discontinuation
- 2014-01-29 FI FIEP20168207.7T patent/FI3712264T3/fi active
- 2014-01-29 EP EP24168742.5A patent/EP4406536A3/en active Pending
- 2014-01-29 WO PCT/US2014/013602 patent/WO2014120770A1/en not_active Ceased
- 2014-01-29 DK DK20168207.7T patent/DK3712264T5/da active
- 2014-01-29 EP EP14705634.5A patent/EP2951299B1/en active Active
- 2014-01-29 EP EP20168207.7A patent/EP3712264B1/en active Active
- 2014-01-29 CN CN201480006554.0A patent/CN105452457A/zh active Pending
- 2014-01-29 JP JP2015555429A patent/JP6453243B2/ja active Active
- 2014-01-29 CN CN202011103747.1A patent/CN112574982B/zh active Active
- 2014-01-29 PT PT201682077T patent/PT3712264T/pt unknown
- 2014-01-29 HK HK16101148.1A patent/HK1213291A1/zh unknown
- 2014-01-29 AU AU2014212471A patent/AU2014212471B2/en active Active
-
2015
- 2015-04-15 US US14/687,389 patent/US9447406B2/en active Active
- 2015-07-05 IL IL23978315A patent/IL239783B/en active IP Right Grant
-
2016
- 2016-08-12 US US15/235,355 patent/US10046036B2/en active Active
-
2018
- 2018-07-02 US US16/025,652 patent/US10624959B2/en active Active
- 2018-12-12 JP JP2018232350A patent/JP2019059768A/ja not_active Withdrawn
-
2020
- 2020-01-31 AU AU2020200719A patent/AU2020200719B2/en active Active
- 2020-10-07 JP JP2020169596A patent/JP7240743B2/ja active Active
-
2022
- 2022-11-04 AU AU2022263598A patent/AU2022263598B2/en active Active
-
2023
- 2023-02-27 JP JP2023028266A patent/JP7580822B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL239783B (en) | Enzyme cystathionine beta-synthase for the treatment of homo-cysteine in the devil | |
| IL268340A (en) | Glucosylceramide synthase inhibitors for the treatment of diseases | |
| SG11201601412XA (en) | Compositions and methods for the treatment of presbyopia | |
| SG11201507121RA (en) | Treatment of cataplexy | |
| PT3021838T (pt) | Tratamento para a obesidade | |
| EP3021848A4 (en) | Treatment for melanoma | |
| ZA201508515B (en) | Treatment of coal | |
| GB201304872D0 (en) | Treatment | |
| PL2968478T3 (pl) | Kompozycje i sposoby do leczenia karboksyhemoglobinemii | |
| SG11201603506PA (en) | Treatment of damaged nerve with pten inhibitor | |
| PL2954866T3 (pl) | Cewnik do blokowania nerwu | |
| GB201310755D0 (en) | Therapy | |
| IL241096B (en) | Treatment methods | |
| EP3060206A4 (en) | Methods for treatment of muscular dystrophies | |
| GB201307310D0 (en) | Treatment | |
| IL236870B (en) | History of hydroxystatin for the treatment of osteoarthritis | |
| PL3016948T3 (pl) | 2-acyloaminotiazole do leczenia nowotworów | |
| GB2525530B (en) | Treatment of hard surfaces | |
| AU2013902652A0 (en) | Treatment of minerals | |
| GB201321115D0 (en) | Treatment | |
| GB201309238D0 (en) | Treatment | |
| GB201303721D0 (en) | Compositions for treatment of sleep disorders | |
| AU2013901359A0 (en) | Methods of Treatment | |
| AU2013900784A0 (en) | Treatment | |
| GB201322778D0 (en) | Method of treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |